Bayesian Approaches in Drug Development: Interpreting the 2026 US Food and Drug Administration Draft Guidance for Optimal Dose Finding
Pharmaceutical Statistics · 2026-11 · 25 (6)
DOI: 10.1002/pst.70149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 13.11.2026. Verfasst von Ayon Mukherjee. Beteiligte Einrichtung: Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Development, Clinical Trials as Topic. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research Grant.
Abstract (Originalsprache)
The US Food and Drug Administration (FDA) released a landmark draft guidance in January 2026 entitled ‘Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products’ (Food and Drug Administration 2026)—the first comprehensive regulatory framework for Bayesian primary inference in drug and biologic trials. This Viewpoint critically appraises the Guidance across four dimensions: (1) The regulatory and philosophical tensions in Section IV.A.1, ‘Calibration to Type‐I Error Rate’, with specific improvement recommendations; (2) the Bayesian borrowing framework articulated in Sections III and V, including gaps in dynamic borrowing and effective sample size (ESS) interpretation; (3) the Guidance's synergy with FDA's Project Optimus and the companion dose‐optimisation guidance (August 2024) (Food and Drug Administration 2024), and how Bayesian methods underpin the optimal biological dose (OBD) paradigm; and (4) the limited operational detail in Section III.F for efficacy–toxicity joint models and seamless Phase I/II designs—the design class most capable of OBD identification. It is contended that the Guidance is a historic advance, yet its oncology dose‐finding section devotes most of its operational detail to maximum tolerated dose (MTD)‐oriented designs. A regulatory taxonomy of Bayesian dose‐finding designs and targeted improvements for the final guidance are proposed. The appraisal refers to the nonbinding January 2026 draft text, which may change before finalisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.
ORCID-Profile: Ayon Mukherjee
Förderung
- National Institute for Health and Care Research Grant
Zitieren
APA
Mukherjee, A. (2026). Bayesian Approaches in Drug Development: Interpreting the 2026 US Food and Drug Administration Draft Guidance for Optimal Dose Finding. Pharmaceutical Statistics, 25(6). https://doi.org/10.1002/pst.70149
Vancouver
Mukherjee A. Bayesian Approaches in Drug Development: Interpreting the 2026 US Food and Drug Administration Draft Guidance for Optimal Dose Finding. Pharmaceutical Statistics. 2026;25(6). doi:10.1002/pst.70149
BibTeX
@article{Mukherjee2026,
author = {Mukherjee, Ayon},
title = {Bayesian Approaches in Drug Development: Interpreting the 2026 US Food and Drug Administration Draft Guidance for Optimal Dose Finding},
journal = {Pharmaceutical Statistics},
year = {2026},
volume = {25},
number = {6},
doi = {10.1002/pst.70149}
}
EUVIMED